Form 4: Corcept Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
Summary
- Grant/award: acquired 138 Common Stock at $113.38 ($15,646) on September 1, 2026; holds 16,268 after (Direct).
- Grant/award: acquired 138 Common Stock on September 1, 2026; holds 16,406 after (Direct).
- Tax/exercise-price withholding: disposed of 102 Common Stock at $113.38 ($11,565) on September 2, 2026; holds 16,304 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Atabak Mokari — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Common Stock | 138 | $113 | $15.6K | 16,268 |
| 2026-09-01 | Grant/award | Common Stock | 138 | — | — | 16,406 |
| 2026-09-02 | Tax/exercise-price withholding | Common Stock | 102 | $113 | $11.6K | 16,304 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (138 shares) |
| 2026-09-01 | Grant/award (138 shares) |
| 2026-09-02 | Tax/exercise-price withholding (102 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, neutral, Atabak Mokari
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.